We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MDRNA, Inc. Issued Patent for the Use of Nucleic Acids to Treat Cancer
News

MDRNA, Inc. Issued Patent for the Use of Nucleic Acids to Treat Cancer

MDRNA, Inc. Issued Patent for the Use of Nucleic Acids to Treat Cancer
News

MDRNA, Inc. Issued Patent for the Use of Nucleic Acids to Treat Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MDRNA, Inc. Issued Patent for the Use of Nucleic Acids to Treat Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MDRNA, Inc. has announced that the State Intellectual Property Office of the People's Republic of China (PRC) has issued a Notification of Granting Patent Rights for PRC 200480018784 which includes the use of nucleic acids.

The patent describes modulation of claudins, which are proteins implicated in tumor progression and metastasis.

"China's pharmaceutical markets are growing nearly 20% a year," said J. Michael French, President and CEO of MDRNA. "China has seen significant expansion in both the pharmaceutical and biotech sectors, which provides an ideal environment for our ongoing efforts to seek international R&D collaborations and investment opportunities. With this patent and our recent allowance of a patent covering RNAi-based modulation of JAM-1 for the treatment of cancer we continue to extend our oncology patent estate worldwide."
Advertisement